Audio: MASTERKEY-115: A Complete (But Concise) Update for Melanoma Treatment - Brian Gastman, MD @BrianGastmanMD @GastmanLab @CleClinicLCM #ASCO22 #OncoTwitter

Audio: MASTERKEY-115: A Complete (But Concise) Update for...

Annual Meeting Photo
Annual Meeting
3 meses
6 Visitas
驴Quieres ver esto de nuevo m谩s tarde?
Inicia sesi贸n para agregar este video a una lista de reproducci贸n. Iniciar sesi贸n
0 0
Categor铆a:
Descripci贸n:

Audio: The FDA approval of multiple drugs um for the treatment of metastatic unresectable melanoma led to uh the concept that we should certainly interrogate whether combinations of these drugs could work synergistically together..Read Full Transcript Here

Brian Gastman, MD is a double boarded Plastic Surgeon and Otolaryngologist with additional fellowships in head and neck surgery, microsurgery and cancer research. Currently, Dr. Gastman is the Medical and Surgical Director of the Melanoma & High-Risk Skin Cancer Program at Cleveland Clinic and leads his translational research laboratory at the Lerner Research Institute. In this interview, he speaks about the ASCO 2022 abstract - Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti鈥揚D-1 therapy: MASTERKEY-115.

Overview:

This is a phase 2 open-label, single-arm, multicenter clinical trial to assess the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab after disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting. Subjects will be given talimogene laherparepvec and pembrolizumab until they have a confirmed complete response, the disappearance of all injectable lesions, documented confirmed disease progression per modified immune-related Response Criteria simulating Response Evaluation Criteria in Solid Tumors (irRC-RECIST), intolerance to study treatment, or 102 weeks from the first dose of talimogene laherparepvec and/or pembrolizumab.

馃摵Click to Watch Video

馃攰Click for Audio Only